Neoadjuvant Chemotherapy for locally advanced gastric cancer with S-1/weekly cisplatin

Neoadjuvant Chemotherapy for locally advanced gastric cancer with S-1/weekly cisplatin - Neoadjuvant Chemotherapy for advanced gastric cancer with S-1/weekly cisplatin

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003962

Enrollment

Registered

2010-07-28

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Neoadjuvant chemotherapy of S-1/weekly cisplatin followed by surgical operation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Gastric cancer confirmed by histology or cytology 2. Stage II, IIIA or IIIB (T2 or more) by preoperative diagnosis 3. Resectable with surgical operation 4. Tumor lesion able to be measured or evaluated 5. Performance Status (ECOG) 0-1

Exclusion criteria

Exclusion criteria: 1. Suspect of peritoneum dissemination 2. Severe medical condition 3. Active bleeding from gastrointestinal tract 4. Poor oral intake 5. Malignant tumor of other organs 6. Contraindication for S-1 or cisplatin

Design outcomes

Primary

Measure	Time frame
Antitumor effect before surgery, Safety of neoadjuvant chemotherapy, Safety of surgery after neoadjuvant chemotherapy, Adverse event during surgical operation	—

Secondary

Measure	Time frame
Histological antitumor effect, Type of recurrence, Recurrence-free survival	—

Countries

Japan

Contacts

Public ContactKoji Nozaki MD, PhD

The University of Tokyo Hospital Clinical Research Support Center

knozaki-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026